2020
DOI: 10.21203/rs.3.rs-98106/v1
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Hydroxychloroquine, nitazoxanide and ivermectin have similar effects in early COVID-19: a head-to-head comparison of the Pre-AndroCoV Trial.

Abstract: Background: COVID-19 pandemic requires urgent responses in terms of identification of effective and safe therapies to reduce hospitalization, death, and post-COVID symptoms, while vaccines are not extensively available. Repurposing already existing medications for COVID-19 should be preferred over the development of new drugs due to their inherent advantages of well-established safety profile, familiarity, and cost. Although antiandrogens have strong plausibility to be effective against COVID-19, hydroxychloro… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
8
0
1

Year Published

2020
2020
2022
2022

Publication Types

Select...
4
2

Relationship

5
1

Authors

Journals

citations
Cited by 7 publications
(9 citation statements)
references
References 38 publications
0
8
0
1
Order By: Relevance
“…The change towards more sensitive COVID-19 detection may justify the very few complications in our RCTs, rather than the therapeutic options. This points to the fact that timing of COVID-19 diagnosis and management may play a more important role than the which therapeutic options to be employed, as demonstrated in one of our studies [5]. Considering that: 1.…”
Section: Introductionmentioning
confidence: 78%
See 2 more Smart Citations
“…The change towards more sensitive COVID-19 detection may justify the very few complications in our RCTs, rather than the therapeutic options. This points to the fact that timing of COVID-19 diagnosis and management may play a more important role than the which therapeutic options to be employed, as demonstrated in one of our studies [5]. Considering that: 1.…”
Section: Introductionmentioning
confidence: 78%
“…This is a post-hoc analysis of clinical data collected prospectively from subjects screened for COVID-19 for the Pre-AndroCoV Trial, AndroCov Trial, and without participating in any of the RCTs, but followed the same clinical procolol [2][3][4][5]. Data analyzed included the number of symptoms presented prior to the diagnosis of COVID-19, presence or absence of anosmia or ageusia, and whether there were positive household contacts before the diagnosis.…”
Section: Designmentioning
confidence: 99%
See 1 more Smart Citation
“…The change toward more sensitive COVID-19 detection may justify the very few complications in our RCTs, rather than the therapeutic options. This points to the fact that the timing of the COVID-19 diagnosis and management may play a more important role than which therapeutic options to be employed, as demonstrated in one of our studies [ 5 ].…”
Section: Introductionmentioning
confidence: 88%
“…First, the exact transmission patterns and incubation period remain not entirely unveiled and may vary according to viral mutations, which precludes precise estimations of the disease timing within each infected subject. Second, symptoms in the first stage of COVID-19 are essentially unspecific since clinical manifestations can resemble those usually present in upper respiratory tract infection (URTI), dengue fever, and/or gastrointestinal (GI) infections [2][3][4][5], reducing the chances of a subject being clinically suspected for COVID-19 before more severe stages, unless there was contact with a household known to be positive for COVID-19. Third, researches on COVID-19 have mainly focused on approaches to reduce mortality in already severely affected COVID-19 subjects [1].…”
Section: Introductionmentioning
confidence: 99%